EBITDA

A hedge fund's 2.34% derivatives stake in Alphawave IP suggests a major acquisition by Qualcomm, highlighting a high-stakes battle for key chip IP.

eDreams ODIGEO is cancelling millions of shares, powered by its Prime subscription model. But can it sustain aggressive buybacks while chasing growth?

A minor share sale by a US giant in a UK tech firm reveals the subtle art of institutional investing and the power of regulatory transparency.

Lightbeam's new NCQA prevalidation isn't just a certificate. It's a strategic move reshaping compliance, patient outcomes, and the health tech market.

A V2G pioneer pivots its intelligent software to compete for a massive national energy storage contract in South Korea's booming, high-stakes market.

With a new $2B share buyback and strong dividends, Royal Caribbean isn't just recovering; it's setting a new course for shareholder value and growth.

ThoughtSpot's new suite of BI agents signals a major shift from static reports to autonomous action. But can it overcome the hurdles of trust and adoption?

IDC names Optiv a GRC leader, highlighting a market-wide move from checkbox compliance to integrated, business-driven cybersecurity strategy.

A new report reveals a surprising twist in the AI era: personal recommendations now drive book discovery, as social reading and audiobooks surge.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Beyond the dazzling lights, Seattle's iconic New Year's Eve show is a calculated investment in branding, technology, and regional economic dominance.

Moving from camera expert to platform pioneer, e-con Systems' new Darsi Pro AI box promises to accelerate robotics and intelligent transportation.

ADP's new retirement plan isn't just about lower fees. It's a tech-driven strategy to solve the SMB benefits gap and empower financial advisors.

Beyond GPS, a new breed of smart satellites with on-board AI is delivering real-time data that could revolutionize disaster response and disease tracking.

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

A new partnership aims to unify cybersecurity and operations in smart buildings, but can it solve the deep-rooted trust and vulnerability issues?

With department stores gone, Primaris REIT is betting on a new model: mixed-use hubs with high-value tenants. Is this the future of Canadian retail?

With new clinical data and recent FDA approval, IceCure Medical's tumor-freezing tech is paving a new, less-invasive path for breast cancer treatment.

The ESA's new elite summit, iicon, replaces E3, targeting C-suites to leverage gaming tech across healthcare, finance, and media. What's at stake?

Early Phase 1 data for VTP-1000 shows promise, but can this novel immunotherapy challenge a crowded market and change life for 80 million patients?